Ascendis Pharma GmbH  

Ascendis Pharma is working towards a number of long-term strategic goals, outlined in a plan called “Vision 20/20. This plan reflects our mission to create best-in-class rare disease products that address unmet medical needs by utilizing TransCon technology to improve parent drugs with demonstrated clinical proof-of-concept. With this strategy, we are using our technology to develop potentially best-in-class products with improved efficacy, safety and/or convenience. In addition, we believe our technology enables a higher development success rate compared to traditional drug development. With Vision 20/20, Ascendis plans to:
- Advance our pipeline of three rare disease endocrinology product candidates—each of which address unmet medical needs and have significant market potential.

Kunststoffe, Elastomere, Tüten, Chemie Vertrieb, Kunststoffe und Mineralstoffe Großhandel, Forschung, Kunststoffhandel, Wissenschaft und Forschung, Acrylglas, Export und Import, Mineralstoffe, Pharma-Biotechnologieunternehmen, Chemie, Mineralstoff, Vertrieb, Großhandel, Institute und Forschungsanstalten für Pharmazie, Kunststoff, Wissenschaft, Biotechnologieunternehmen